From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

How is Haleon - the spin-off from GSK plc - doing, punk?

By Chris Bailey of Financial Orbit | Saturday 12 November 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


As per analytical data from my personal pension fund account, I have made money from my choice to retain a holding in Haleon (HLN) - “a global leader 100% focused on consumer healthcare with a competitive advantage to combine deep human understanding with trusted science” - after its spin-off from GSK plc (GSK) in July.  I am not sure that is technically correct given the company’s c. 276.53p share price at the close of business on Friday.  Anyhow, the bigger question is what should I do now?  After all, other GSK shareholders - including Tom - decided to exit stage left kicking around a 300 pence share price immediately after the spin-off and invest elsewhere.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

HAT

H&T Group – now again a Buy

Time left: 11:49:22